Dry eye nasal spray and future of Beovu lead June coverage
Study results showing efficacy of a dry eye nasal spray and a blog pondering the future of Beovu lead ophthalmology coverage for June.
Read the top-performing stories from the first part of the month below.
Nasal spray improves signs, symptoms of dry eye disease
Patients treated with a nasal spray experienced improvement in signs and symptoms of dry eye disease by day 28 of treatment, according to a study. Read more.
BLOG: What’s next for Beovu?
On the heels of the major announcement from Novartis that Beovu should not be used in intervals less than 8 weeks, some are wondering what the ultimate future of the drug will be. Read more.
Lindstrom: Future of cataract surgery in US includes bilateral, in-office procedures
KIAWAH ISLAND, S.C. — Depending on a number of different scenarios, the future of cataract surgery in the U.S. will include in-office immediate sequential bilateral cataract surgery. Read more.
Cosmetic keratopigmentation shows long-term efficacy, satisfaction
Cosmetic keratopigmentation showed efficacy and high patient satisfaction in a large prospective series of patients with a follow-up of 1 to 6 years. Read more.
FDA accepts NDA for Xipere
The FDA has accepted a resubmitted new drug application for Xipere for the treatment of macular edema associated with uveitis, according to a press release from Bausch + Lomb and Clearside Biomedical. Read more.